Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma
Status:
Completed
Trial end date:
2007-12-17
Target enrollment:
Participant gender:
Summary
There will be approximately 14,000 new patients with invasive cervical cancer diagnosed in
the United States in 2003 with about 4,000 deaths from this disease. This accounts for
approximately 17% of all deaths due to gynecologic cancers. Radiation has been the primary
treatment modality for locoregionally advanced cervical cancer. Recent trials of concomitant
systemic cisplatin chemotherapy and radiation have shown high response rates (RR) with
improvements in durable remissions and overall survival. Though the incidence and mortality
in the U.S. dropped steadily from years 1940 to 2000, there has recently been a plateau,
arresting the decline. With the routine addition of systemic Cisplatin (CDDP) chemotherapy to
local regional radiation, mortality from advanced cervical cancer in the United States is
expected to further decrease. However, further advances in this disease are needed.